Amicis Research Center | Northridge, CA

Research site

(Unclaimed)

Location

9241 Reseda Boulevard Suite B, Northridge, California, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Lorundrostat

BI 690517

GFB-887

Bardoxolone Methyl

Aprocitentan

IMG-007

CT-388

Ruxolitinib

Tildrakizumab

Parent organization

This site is a part of Amicis Research Center

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 30 total trials

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematous in adult patients with moderate to sever...

Active, not recruiting

Lupus Erythematosus, Systemic

Drug: Cenerimod

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Phase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.

Active, not recruiting

Moderate to Severe Genital Psoriasis

Drug: Tildrakizumab 100 mg

Drug: Placebo

A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy (ALMOND)

The primary objectives of this study are: In Part 1 to evaluate the efficacy of zanubrutinib as measured by proteinuria reduction, and in Part 2 to e...

Active, not recruiting

Primary Membranous Nephropathy

Drug: Tacrolimus

Drug: Zanubrutinib

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People ca...

Enrolling

Heart Failure

Drug: Placebo

Drug: empagliflozin

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes (CATT1)

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

Enrolling

Diabetes Mellitus, Type 1

Drug: Cadisegliatin 800 mg QD

Drug: Placebo

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (AIRCULES)

This is a Phase 2b, global, multicenter, randomized, double-blind, placebo-controlled, parallel group, dose ranging study to assess the efficacy, saf...

Active, not recruiting

Asthma

Drug: Placebo

Drug: Lunsekimig

Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

Multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of BION-1301 in healthy volunteers...

Active, not recruiting

IgA Nephropathy

Drug: BION-1301 Multiple Doses

Drug: Placebo Multiple Doses

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease (ANCHOR-POC)

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have dia...

Enrolling

Diabetic Kidney Disease (DKD)

Drug: Evinacumab

Drug: ALN-ANG3 placebo